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ess: Doug@LCFresearchSummary We conducted a historical cohort study to examine the relationship between
survival and use of inhaled corticosteroids (ICS) and/or long-acting beta agonists (LABA) in
patients with chronic obstructive pulmonary disease (COPD). All COPD patients agedX40
years who were enrolled in one of two regional managed care organizations during
1995–2000, and who had X90 days use of an ICS and/or LABA (N ¼ 1288) or of a short-
acting bronchodilator (N ¼ 397), were identified. Of patients treated with ICS and/or
LABA, 14.4% died during the follow-up period, as compared to 28.2% of comparison
patients (Po0:01). In a Cox proportional hazards model that controlled for age, sex,
comorbidities, COPD severity, and asthma status, a reduced risk of death was found for
ICS treatment (HR 0.59 [95% CI 0.46–0.78]), LABA (HR 0.55 [0.34–0.89]), and ICS plus
LABA treatment (HR 0.34 [0.21–0.56]). A second model that excluded any patient who
also had an ICD-9 code for asthma (N ¼ 840) still found improved survival among those
using the combination of ICS plus LABA (HR 0.35 [CI 0.17–0.71]). Additional analyses that
varied the exposure criteria also found a consistent treatment benefit. Inclusion of ICS or
bronchodilator treatment during the follow-up period as a time-dependent function
appears to negate the survival benefit; however, the underlying assumptions for valid
time-dependent modeling are clearly violated in this situation. In conclusion, we found
that COPD patients who used ICS alone or in combination with LABA had substantially
improved survival even after adjustment for asthma and other confounding factors.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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It is well accepted that inflammation plays an
important role in the pathogenesis of chronic
obstructive pulmonary disease (COPD).1–4 However,
the use of inhaled corticosteroids (ICS) in COPD
treatment remains controversial, and the data
regarding their efficacy inconsistent.5–7 In stable
COPD patients, ICS have reduced inflammatory
cells and cytokines in some clinical trials8–13 but
not others.14,15 Large clinical studies have found
that ICS improve baseline lung function, reduce the
frequency or severity of COPD exacerbations,16–19
decrease the rate of decline in health status,18,20,21
and reduce chronic respiratory symptoms.22 When
combined with long-acting beta agonists (LABA),
they result in significantly improved baseline lung
function, even among those who do not have
significant airflow improvement with inhaled albu-
terol at baseline.23–27 However, skeptics note that
ICS have very little effect on the rate of decline in
lung function,18,22,28–30 a benefit that has only been
found significant after meta-analysis.31 Uncertainty
about the merits of ICS is reflected in current COPD
treatment guidelines, which recommend their use
only in patients who have an FEV1 less than 50% of
predicted and frequent exacerbations.1,2
Several retrospective analyses of ICS use among
COPD patients have examined the association
between ICS use and survival, an outcome not
included in the design of previously reported
randomized clinical trials, and found mixed results.
In a review of 22,620 residents of Ontario, Canada
who were aged 65 years and older and hospitalized
for COPD at least once, patients who received ICS
within 90 days of hospital discharge had a substan-
tially lower adjusted relative risk (RR 0.74 [95% CI,
0.71–0.78]) for repeat hospitalization or death
compared to those who did not receive ICS.32 In a
study based on the United Kingdom General
Practice Research Database (GPRD), 1045 COPD
patients who were regular users of salmeterol and/
or fluticasone propionate had significantly better 3-
year survival than 3620 COPD patients not using ICS
or LABA (78.6% versus 63.6%), after adjustment for
age, sex, smoking, comorbidities, and asthma.33
More recent studies have criticized the methods
used in these prior analyses and have suggested
that immortal time bias and their intent-to-treat
design have resulted in the apparent treatment
benefit.34–36 These studies have included ICS treat-
ment as a time-dependent factor in Cox propor-
tional hazards (CPH) models and found that inhaled
steroids did not have a survival benefit. However,
time-dependent analysis is a technique that as-
sumes that exposure to treatments is not related toother clinical factors that are likely to affect
survival, which is unlikely in this situation, and
may in fact introduce bias into an analysis rather
than control for it when this assumption is
violated.37 None of these previous studies have
addressed the problem of the overlap between
COPD and asthma, even though some have sug-
gested that COPD patients who have increased
bronchial hyperresponsiveness have worse survi-
val.38,39
To further explore these issues, we conducted a
study using longitudinally collected data from two
managed care databases from two separate regions
in the United States. We identified all COPD
patients who were treated with either ICS, LABA,
or ICS plus LABA, using for comparison all COPD
patients who were never treated with these drugs
but who were treated with short-acting bronchodi-
lators. We then analyzed these populations using
standard survival analysis techniques to address the
following questions: (1) does use of ICS and/or LABA
improve survival among COPD patients? (2) does
any benefit persist after adjustment for asthma,
smoking, and other clinical factors likely to affect
survival? (3) will factors that could introduce bias,
such as differences in the case accrual period or the
duration of baseline exposure, have a significant
effect? and (4) how does inclusion of ICS treatment
as a time-dependent variable in the survival model
affect the apparent survival benefit, and are the
underlying assumptions for the time-dependent
analysis technique satisfied?Methods
Study subjects
The study was conducted in two managed care
populations: the Lovelace Health Plan (LHP), a
group and network model HMO in New Mexico with
approximately 240,000 members in 2001; and the
Kaiser Permanente Georgia Health Plan, a group
and network model HMO in Atlanta with approxi-
mately 280,000 members in 2001.
Study subjects were members of either health
plan at any time during the study period (January 1,
1995–December 31, 2000), were aged 40 years or
older, and had a diagnosis of COPD, which was
defined as having had at least two outpatient
encounters or one hospital admission coded as
chronic bronchitis (ICD-9 code 491.x), emphysema
(492.x), or COPD (496) during the study period. The
date on which the patient met the COPD diagnosis
criterion was designated the ‘‘study eligibility
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COPD survival and inhaled corticosteroids 597date’’. Patients with cystic fibrosis, bronchiectasis,
or lung cancer were excluded.
Using pharmacy claims, we captured each pa-
tient’s respiratory drug utilization beyond the study
eligibility date (the accrual period) and determined
the dates and duration of treatment. Subjects in
the treated groups had at least 90 days cumulative
treatment following their study eligibility date to:
(1) ICS alone, (2) LABA alone, or (3) ICS plus LABA.
In the two study HMOs, salmeterol was the only
LABA used for treatment of COPD patients. Com-
parison subjects had no pharmacy claims for ICS or
LABA during the entire study period, but had at
least 90 days cumulative treatment to a short-
acting beta-agonist, ipratropium, a combined albu-
terol/ipratropium inhaler, or theophylline during
the accrual period.Follow-up period
Follow-up began on the first day following the
90th day of drug treatment and continued until
death, disenrollment from the health plan, or
December 31, 2000, whichever occurred first.
Patients were required to have been a health plan
member for the entire 12-month period prior to the
point at which they accumulated 90 days of
respiratory drug exposure in order to permit
capture of baseline comorbidities and health status
characteristics. A minimum follow-up period of 30
days was required for entry into the cohort.Data collection
Death records for the COPD cohort were obtained
from state vital statistics records for the years
1995–2000. Records were matched on name, date
of birth, and social security number. In cases where
the accuracy of a death match was questionable,
we examined enrollment and utilization records of
the probable decedent to determine accuracy of
the match.
Information on smoking history, smoking status,
asthma status, asthma severity, COPD severity,
other respiratory conditions requiring hospitaliza-
tion, and comorbidities were collected from med-
ical charts and administrative claims records. We
reviewed the written and electronic medical
records of 1178 patients (840 in the treated group
and 338 in the comparison group) and abstracted
information at baseline (the year prior to the start
of the patient’s follow-up period), including smok-
ing history (pack-years), smoking status (never
smoked, former smoker, current smoker), presence
of an asthma diagnosis, and pulmonary function.The medical record reviewers at both study sites
were trained in the use of a detailed data
collection protocol prior to record abstraction.
We used claims records of COPD-related out-
patient encounters and hospitalizations to develop
a proxy measure of COPD severity, since pulmonary
function tests were not available for all patients.
COPD severity at baseline (the year prior to the
start of the patient’s follow-up period) was based
on the number of COPD outpatient encounters,
COPD emergency department encounters, and
hospital admissions with a primary discharge
diagnosis of COPD, with the assumption that a
higher level of COPD-related utilization repre-
sented greater disease severity. A similar proxy
variable for baseline asthma severity was created
based on the number of asthma outpatient en-
counters, asthma emergency department encoun-
ters, and hospital admissions with a primary
discharge diagnosis for asthma (ICD-9 493.xx).
Respiratory admissions for conditions other than
COPD or asthma were counted using relevant
discharge codes (ICD-9 460–490, 495, 500–519).
To adjust for comorbidities, a comorbidity score
for each patient was calculated using the Deyo
adaptation of the Charlson index40 with the
respiratory disease diagnosis code group removed
from the index. This index was originally developed
to predict risk of death in hospitalized patients and
includes 17 groups of comorbidities, each given a
weighted value. We calculated the score in two
ways: (1) using hospitalization diagnosis codes only
(patients with no admissions received a score of (0)
and, (2) using outpatient encounter diagnosis
codes. For the outpatient score, we required that
two encounters with a given comorbidity diagnosis
be present on separate dates in order for that
comorbidity to be considered present. This served
to exclude diagnosis codes in the claims records
that represented a ‘‘rule-out’’ rather than actual
diagnosis.
Exacerbations were captured during the follow-
up period in order to examine the assumption of
independence between respiratory drug use, ex-
acerbations, and death. An exacerbation was
defined as an outpatient visit for a respiratory
illness that resulted in a prescription fill for an
antibiotic or oral corticosteroid within 2 days, or an
emergency department visit or hospitalization for a
respiratory illness.Analysis
The overall approach was to build a CPH model
using standard survival analysis methods that would
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groups after adjustment for other factors likely
to affect survival.41,42 Additional models were
then created to examine the various potential
biases that could have caused or contributed to
the apparent survival benefit. The data were
collected and the results analyzed using PC SASs
version 8.2 (SAS Institute, Cary, NC). Differences
in the demographic and clinical characteristics
between the treated and comparison popula-
tions were tested for statistical significance using
the w2 test for proportions, the Student’s t-test
for normally distributed continuous measures, and
the Wilcoxon test for non-normally distri-
buted variables (Tables 1 and 2), as were the
characteristics of patients who survived and died
(Table 3).
The main survival model was developed using the
PHREG procedure in SASs. Death was the depen-
dent variable and the following were independent
variables: age, sex, ICS treatment, LABA treat-
ment, ICS plus LABA treatment, asthma diagnosis,
measures of COPD severity at baseline, measures of
asthma severity at baseline, hospitalization for
respiratory illnesses, and both inpatient and out-
patient Charlson–Deyo scores. Four additional
models were developed: (1) a model that excluded
patients with any diagnosis of asthma; (2) a modelTable 1 Demographic and clinical characteristics of t
comparison (short-acting bronchodilator only) groups.
Characteristic Treated,
Lovelace HMO member 69.0%
Mean age 67.4 (71
Male 49.7%
Asthma diagnosis 58.8%
Mean hospital Charlson score 0.30 (7
Mean outpatient Charlson score 0.43 (7
Percent with hospitalization in prior year 38.3%
Died during study period 14.4%
Ever smokedy 90.2% [80
Current smokery 29.6% [71
Mean pack-yearsy 57.4 (73
Gold stage, meany 2.7 [346
Stage 0 (at risk) 5.5%
Stage 1 (mild) 1.7%
Stage 2 (moderate) 32.1%
Stage 3 (severe) 41.0%
Stage 4 (very severe) 19.7%
Parentheses ¼ standard deviation.
Brackets ¼ absolute number.
Had one or more outpatient encounters or hospitalizations wit
follow-up.
yBased on data obtained from chart abstraction.that examined the effects of variable smoking
exposures; (3) a model that examined the effects of
a limited (12 months) accrual period, or a shorter
or longer cumulative exposure; and (4) a model
that included all the variables found in the main
model but also included ICS and LABA treatment
during the follow-up period as a time-dependent
variable. The adjusted survival functions for the
main model (Fig. 1) and main model without
asthma patients (Fig. 2) were generated using the
PHREG procedure in SASs.
To test the assumptions of the proportional
hazards model, we plotted the log–log survival
functions and the 120-day smoothed hazard func-
tions.42 We found that the proportional hazards
assumption was satisfied for the entire follow-up
period for the ICS alone, ICS plus LABA, and
reference groups. The hazard function for the
LABA alone group during the 1–400 day follow-
up period crossed the other two treated groups,
and thus the hazard ratio estimate for the
LABA group actually varies across the study
interval, although its hazard function was
consistently above that of the comparison group
(Tables 4–6). To compare the fit of alternative
models against the observed data, we used the
minus twice the logarithm of the maximized like-
lihood statistic.41he treated (ICS, LABA, or combined ICS/LABA) and
N ¼ 1288 Comparison, N ¼ 397 P-value
68.5% 0.84
0.4) 69.9 (710.2) o0.001
55.7% 0.04
22.2% o.001
0.66) 0.41 (70.90) 0.08
0.93) 0.50 (70.88) 0.25
37.0% 0.65
28.2% o0.001
2] 92.1% [327] 0.32
9] 36.1% [294] 0.05
2.3) [604] 60.5 (731.0) [239] 0.20
] 2.5 [55] 0.18
5.5% 0.99
7.3% 0.01
40.0% 0.27
29.1% 0.08
18.2% 0.80
h an ICD-9 billing code for asthma (493.x) in the year prior to
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Table 2 Average outpatient encounters, inpatient admissions, and short-acting beta-agonist inhaler use among
treated and comparison COPD groups in the 12 months prior to follow-up.
Characteristic Treated group,
N ¼ 1288
Comparison group,
N ¼ 397
P-value
Mean (std dev) Mean (std dev)
COPD outpatient encounters 11.7 (714.5) 10.4 (716.5) 0.12
COPD emergency dept. encounters 0.10 (70.40) 0.12 (70.54) 0.43
COPD admissions 0.27 (70.67) 0.30 (70.85) 0.44
Respiratory symptom admissions 0.15 (70.45) 0.16 (70.57) 0.68
Asthma outpatient encounters 3.3 (76.4) 0.67 (73.1) o0.001
Asthma emergency dept. encounters 0.06 (70.36) 0.02 (70.12) 0.01
Asthma admissions 0.11 (70.45) 0.03 (70.23) o0.001
Percent using short-acting beta-agonist 78.3% 83.1% 0.04
Mean total days supply of short-acting beta-
agonist
148 (7136) 89 (741) o0.001
Median total days supply of short-acting beta-
agonist
105 91 o0.001
An encounter is a billable procedure and includes face-to-face physician visits, radiology procedures, and laboratory
procedures.
Table 3 Clinical factors independently associated with survival in the overall COPD cohort.
Survivors, N ¼ 1388 Deceased, N ¼ 297 P-value
Age on first day of follow-up 66.7 74.3 o0.001
Male gender 50.0% 55.9% 0.07
Asthma diagnosis 53.1% 36.4% o0.001
LHP patient 66.5% 78.4% o0.001
Charlson–Deyo score, hospital-based 0.10 0.23 0.004
Charlson–Deyo score, outpatient-based 0.42 0.58 0.009
Hospitalized for any reason 48.1% 55.2% 0.03
Hospitalized for COPD 17.0% 32.3% o0.001
Hospitalized for asthma 7.8% 4.7% 0.06
X20 COPD outpatient encounters 16.0% 31.6% o0.001
X2 asthma outpatient encounters 36.7% 19.5% o0.001
X1 emergency dept. visit for COPD 7.1% 10.1% 0.07
X1 emergency dept. visit for asthma 3.7% 2.4% 0.26
Current smokers 34.1% 22.5% o0.001
Cigarette pack-years 57.9 59.7 0.44
Percent of predicted FEV1
 48.7 39.7 0.001
ICS usey 46.3% 48.2% 0.57
LABA usey 10.8% 6.7% 0.03
ICS and LABA usey 22.3% 7.4% o0.001
All figures are expressed as the mean unless noted as a percentage (%). All P values are for row comparisons.
Limited to those who had information available in the medical record.
yMinimum of 90 days of treatment prior to follow-up period.
COPD survival and inhaled corticosteroids 599Results
We identified 1288 patients who met eligibility
criteria for the treated group (786 with ICS
treatment, 170 with LABA treatment, and 332 with
ICS plus LABA treatment) and 397 who meteligibility criteria for the comparison group. The
Lovelace HMO contributed disproportionately more
COPD patients to the study (69% versus 31%), partly
due to the older age distribution of its membership.
The percentages of treated and comparison pa-
tients from each HMO were comparable.
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Figure 1 The adjusted survival function for COPD
patients using inhaled corticosteroids (ICS), long-acting
beta agonists (LABA), or both (ICS–LABA), versus patients
using only short-acting bronchodilators (minimum of 90
days of therapy in each group prior to follow-up).
Figure 2 The adjusted survival function for COPD
patients in the treatment and comparison groups after
excluding all persons with any ICD-9 code for asthma
(minimum of 90 days of therapy in each group prior to
follow-up).
D.W. Mapel et al.600The demographic and clinical characteristics of
the groups are shown in Table 1. The treated group
was slightly younger, had a lower proportion of
men, and had a much higher proportion of patients
who also had a ICD-9 code for asthma in the 12
months prior to follow-up (Po0:05 for each
comparison). The combination ICS–LABA grouphad the highest prevalence of a concurrent asthma
diagnosis (65.0%), which was significantly higher
than those in the ICS group (51.0%), but not higher
than the LABA group (59.0%). The groups did not
differ substantially in comorbidity status as mea-
sured by the inpatient or outpatient Charlson–Deyo
index, and the proportion of either group hospita-
lized in the 12 months prior to follow-up was also
very similar. The mean follow-up period for all
patients was 673 days. The accrual periods for the
ICS, LABA, and comparison groups were very similar
(median accrual days: 182, 168, and 169, respec-
tively). However, the time needed to accrue the 90
days of exposure to both ICS and LABA for entrance
into the combined group was much longer (421
days). Almost twice as many patients in the
comparison group died during the follow-up period
(28.2% versus 14.4% among the treated groups;
Po0:0001).
Based on medical records abstracted from 1178
out of 1685 patients, a slightly higher proportion of
the comparison group was still using cigarettes in
the year prior to follow-up, but the treated and
comparison groups did not differ substantially by
total pack-year smoking history (Table 1). Only 425
patients had a complete pulmonary function test in
their medical charts that was obtained in the 12
months prior to follow-up. For those with spirome-
try data, the distributions of disease severity using
the GOLD classification system were similar for the
treated and comparison patients. A slightly higher
percentage of comparison patients had mild dis-
ease (FEV1/FVC ratio o0.7 and FEV1480% pre-
dicted) while slightly more treated patients had
severe or very severe disease (FEV1o50% or o30%
predicted, respectively).
The healthcare utilization of the treated and
combined comparison groups in the 12 months prior
to follow-up is shown in Table 2. The treated and
untreated groups did not differ in the average
number of COPD-related outpatient encounters,
COPD-related emergency department encounters,
or hospital admissions for either a COPD or other
respiratory diagnosis. The treated patients, how-
ever, had more asthma-related outpatient encoun-
ters, asthma-related emergency department
encounters, and hospital admissions with an asthma
diagnosis. A total of 38.3% of treated and 37.0% of
comparison patients had a hospitalization for any
reason in the year prior to follow-up, a difference
that was not statistically significant. Although only
78.3% of the treated groups were dispensed a short-
acting bronchodilator during the 12 months prior to
follow-up, patients in the treated groups who used
them were dispensed a higher average days supply
of inhalers.
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Table 4 Main Cox proportional hazard model for death for COPD patients using inhaled corticosteroids (ICS),
long-acting beta agonists (LABA), or both (ICS plus LABA) vs. patients only using short-acting bronchodilators
(N ¼ 1685).
Variable Hazard ratio 95% confidence limits w2 Pr4w2
ICS 0.59 0.46 0.78 14.77 o0.001
LABA 0.55 0.36 0.89 5.87 0.02
ICS plus LABA 0.34 0.21 0.56 18.74 o0.001
Lovelace HMO member 1.41 1.03 1.93 4.63 0.03
57–65 years old 1.90 0.97 3.73 3.51 0.06
66–72 years old 2.15 1.12 4.13 5.23 0.02
472 years old 4.34 2.32 8.12 20.99 o0.001
Male 1.09 0.87 1.38 0.55 0.46
3–19 COPD outpatient encounters 2.07 1.44 2.99 15.24 o0.001
X20 COPD outpatient encounters 3.38 2.25 5.08 34.27 o0.001
X1 COPD emergency dept. encounter 1.28 0.84 1.96 1.32 0.25
X2 COPD hospitalizations 1.35 0.88 2.06 1.91 0.17
X1 respiratory hospitalization 1.11 0.78 1.57 0.32 0.57
X2 asthma outpatient encounters 0.67 0.49 0.92 6.06 0.01
X1 asthma emergency dept. encounter 1.00 0.45 2.20 0.00 1.00
X1 asthma hospitalization 0.97 0.56 1.70 0.01 0.92
Charlson score X1 based on hospitalizations 1.26 0.88 1.83 1.56 0.21
Charlson score X1 based on outpatient encounters 1.12 0.86 1.46 0.75 0.39
Minimum 90 days treatment with any of the study medications prior to follow-up period required.
Table 5 Main hazard model after excluding all COPD patients who ever also had an asthma (N ¼ 840).
Variable Hazard ratio 95% confidence limits w2 Pr4w2
ICS 0.74 0.54 1.02 3.35 0.07
LABA 0.60 0.33 1.09 2.77 0.10
ICS plus LABA 0.35 0.17 0.71 8.43 0.004
Lovelace HMO member 1.35 0.88 2.07 1.92 0.17
57–65 years old 1.12 0.48 2.63 0.07 0.79
66–72 years old 1.43 0.63 3.24 0.71 0.40
472 years old 3.00 1.37 6.58 7.51 0.01
Male 1.16 0.86 1.56 0.92 0.34
3–19 COPD outpatient encounters 1.72 1.10 2.67 5.70 0.02
X20 COPD outpatient encounters 2.79 1.69 4.60 16.08 o0.001
X1 COPD emergency dept. encounter 1.11 0.61 2.03 0.12 0.73
X2 COPD hospitalizations 1.99 1.15 3.45 6.00 0.01
X1 respiratory hospitalization 0.75 0.44 1.26 1.17 0.28
Charlson score X1 based on hospitalizations 0.96 0.59 1.57 0.02 0.88
Charlson score X1 based on outpatient encounters 1.06 0.76 1.48 0.14 0.71
*Minimum 90 days treatment with any of the study medications prior to follow-up period required.
COPD survival and inhaled corticosteroids 601Survival analysis
An unadjusted comparison of factors associated
with death is presented in Table 3. As expected,
older patients were at higher risk of death; the
average age at the time of death was 76.8 (79.7)
years. A slightly higher proportion of deceased
persons were men, although the difference did notquite reach statistical significance. Compared to
patients who died, the survivors were more likely
to have had concurrent diagnosis of asthma and had
fewer chronic comorbid conditions, as indicated by
either the hospital-based or outpatient Charlson–
Deyo index. Hospitalization in the year prior to
follow-up was associated with a higher risk of
death, especially if it was primarily for COPD.
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Table 6 Main model with a 12-month limited case accrual period, a 60-day treatment period, and a 180-day
treatment period.
Subcohort with X90 days
drug treatment accumulated
within 1 year (N ¼ 1192)
60 days drug treatment
criterion* (N ¼ 1405)
180 days drug treatment
criterion (N ¼ 1162)
Hazard ratio Pr4w2 Hazard ratio Pr4w2 Hazard ratio Pr4w2
ICS 0.55 o0.001 0.68 0.01 0.56 o0.001
LABA 0.52 0.02 0.60 0.05 0.43 0.01
ICS plus LABA 0.42 0.01 0.41 o0.001 0.25 o0.001
Lovelace HMO member 1.39 0.06 — — 1.04 0.84
57–65 years old 1.64 0.17 3.64 0.03 1.62 0.21
66–72 years old 1.82 0.09 3.89 0.02 1.87 0.10
472 years old 3.61 o0.001 8.04 o0.0014 4.11 o0.001
Male 1.16 0.26 1.00 1.00 1.34 0.05
3–19 COPD outpatient
encounters
2.33 o0.001 1.74 0.002 2.03 0.003
X20 COPD outpatient
encounters
3.50 o0.001 2.99 o0.001 2.92 o0.001
X1 COPD emergency
dept. encounter
1.15 0.57 2.39 0.001 1.21 0.45
2 COPD hospitalizations 1.42 0.14 1.45 0.14 1.32 0.24
X1 respiratory
hospitalization
1.11 0.61 1.33 0.14 1.30 0.19
X2 asthma outpatient
encounters.
0.71 0.05 0.65 0.90 0.59
X1 asthma emergency
dept. encounter
0.85 0.74 0.80 0.77 0.93 0.88
X1 asthma
hospitalization
0.95 0.86 0.85 0.62 1.06 0.87
Charlson score X1
based on
hospitalizations
1.39 0.11 1.17 0.42 2.00 1.00
Charlson score X1
(outpatient encounters
only)
1.20 0.23 1.26 0.10 1.04 0.82
D.W. Mapel et al.602Hospitalizations that included asthma among the
discharge diagnoses, or having two or more out-
patient visits coded for asthma were associated
with a reduced risk of death. Persons who were still
smoking in the year prior to follow-up had a lower
risk of death, most likely because they tended to be
younger and have less severe lung disease. The
percent of predicted FEV1 was an independent
predictor of survival even though baseline spiro-
metry data were available for less than half of the
cohort.
The results of the main Cox model estimating the
hazard ratios for ICS, LABA, or combined treatment
as compared to the comparison group, after
adjustment for most of the factors associated with
death in the previous analysis, are presented in
Table 4. A significantly reduced risk for death was
found for ICS treatment, LABA treatment, and ICSplus LABA treatment. In this model, LHP patients
had poorer survival than the Kaiser–Georgia pa-
tients, which may represent residual confounding
due to the higher proportion of older persons in the
Lovelace HMO. Among the utilization factors
included to adjust for COPD and asthma severity,
the number of outpatient encounters for COPD had
the strongest association with survival. The ad-
justed survival plot from this model is presented in
Fig. 1.
The second model simply excluded all COPD
patients who ever had an ICD-9 code for asthma
(Table 5). The hazard ratios for the three treatment
groups changed very little from the previous model.
However, because the total population was cut by
a little over half, the 95% confidence intervals
are wider, and now only the hazard ratio for the
combined ICS/LABA treatment group reaches the
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Figure 3 The proportions of patients in the treated and
comparison groups who had at least one exacerbation
during the follow-up period, by survival status (ICS:
inhaled corticosteroid; LABA: long-acting bronchodilator;
SABD: short-acting bronchodilator).
COPD survival and inhaled corticosteroids 603arbitrary set point for statistical significance. As
compared to the first model, the hazard ratios for
persons in the younger age groups fell substantially
and were no longer significant, while two or more
COPD admissions in the year before follow-up
became significant. The adjusted survival plot for
this comparison is shown in Fig. 2.
The third model examined the effect of variable
smoking exposure (data not shown). This included
only patients for whom smoking pack-year history
was available from medical records (N ¼ 1178). In
the bivariate comparisons (Table 3) current smo-
kers actually had better survival. However, after
adjustment for age and the other factors included
in the main model, neither smoking pack-years nor
status had a significant effect on survival. ICS alone
(HR 0.73 [95% CI: 0.55, 0.96]) and combined ICS/
LABA therapy (HR 0.44 [95% CI: 0.26, 0.74]) were
both associated with a significant survival benefit in
this model.
The models in Table 6 examine the effects of a
limited (12 months) accrual period and a shorter or
longer minimum cumulative treatment exposure on
the main model. Requiring that patients accumu-
late their 90 days of respiratory drug treatment
within 12 months resulted in very little change from
the results of the main model (Table 4), even
though 493 of the patients from the main survival
model were excluded by this additional criteria.
Decreasing the minimum exposure criterion to 60
days caused the hazard ratio estimates for the ICS
and LABA groups to increase slightly, although they
continued to show a statistically significant treat-
ment benefit. Emergency department visits in the
year prior to follow-up were associated with a
higher risk for death only when the exposure
requirement is lowered to 60 days, suggesting that
more limited exposure requirements are likely to
introduce unstable patients who have a higher risk
of death. When the exposure criterion for treated
and comparison patients was extended to 180 days,
the hazard ratios for all three treatment groups
went even lower and were still highly statistically
significant even after the loss of 523 patients as
compared to the main model. Male gender became
a significant risk factor only in the 180-day
exposure analysis, suggesting that some gender
bias can be introduced if very long cumulative
exposures are required. Even when the 60 day
exposure and a 12 month accrual criteria were
simultaneously applied to the LHP cohort
(N ¼ 1064, data not shown), the hazards ratio
estimates for all three treatment groups changed
very little (ICS alone, 0.59; LABA alone, 0.51; ICS
plus LABA, 0.31), and the statistical significance
was also preserved despite the loss of power.Treatment as a time-dependent covariate
We then explored the issue of including treatment
during the follow-up period as a time-dependent
variable in the main model. To test the funda-
mental assumption in time-dependent modeling
that the changes in exposure to treatment are
independent of the patient’s health status, we
compared respiratory medication use, exacerba-
tions, and their association with death during the
follow-up period. We found a strong association
between respiratory medication use and exacerba-
tion events: 39% of the inhaler fills during the
follow-up period occurred within 2 days of a clinic
or emergency department visit for a respiratory
illness. All treated patients combined were more
likely than the comparison group to have an
exacerbation during the follow-up period (61%
versus 46%, Po0:01), although the ICS group was
the only individual group that had a statistically
higher proportion of exacerbations among both
survivors and decedents (Fig. 3).
There was also a significant relationship between
exacerbations and death: patients who died aver-
aged 0.19 exacerbations per month, while survivors
averaged 0.07 (Po0:001). We also found that
persons who died had a substantially higher rate
of bronchodilator use (0.68 inhalers per month
versus 0.24, Po0:001) and ICS use (0.49 inhalers
per month versus 0.20, Po0:001) during the follow-
up period. Therefore, changes in respiratory
medication use are in fact quite commonly related
to changes in health status during the follow-up
period, and therefore the independence assump-
tion necessary for valid time-dependent modeling
is violated. Treatment decisions made by physicians
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outcome, in this case death.
Although we have demonstrated that time-
dependent modeling is not valid in this situation,
we created a model that included treatment during
the follow-up period as a time-dependent covariate
in order to demonstrate how including a con-
founded factor affected the results. To simplify
the comparisons, we limited the cohorts in this
table to the ICS alone group and the comparison
(short-acting bronchodilator) groups only, exclud-
ing all patients who were treated with LABA (Table
7). In this model, the hazard ratio for ICS use during
the baseline period is higher than that of the main
model (0.73 versus 0.59) and it has lost its
statistical significance. Also, ICS use during the
follow-up period appears to have no benefit at
all (hazard ratio: 1.04). However, note that
continued bronchodilator use among patients in
the comparison group during the follow-up period is
associated with a trend towards worse survival
(hazard ratio: 1.41). The goodness of fit of the
time-dependent model was slightly poorer than
that of the basic model (the minus twice the
logarithm of the maximized likelihood statistic:
2781 versus 2783) and the P-value of the compar-
ison was not statistically significant. Similar results
were found in a model that used either ICS or
LABA in the follow-up period as time-dependent
covariates.Table 7 Main model with a time-dependent variable fo
comparison group (N ¼ 1183).
Variable
ICS vs. comparison group
ICS use by ICS group during follow-up
Comparison drug use by comparison group during follow-u
HMO 1 member
57–65 years old
66–72 years old
472 years old
Male
3–19 COPD outpatient encounters
X20 COPD outpatient encounters
X1 COPD emergency dept. encounter
X2 COPD hospitalizations
X1 respiratory hospitalization
X2 asthma outpatient encounters
X1 asthma emergency dept. encounter
X1 asthma hospitalization
Charlson score X1 based on hospitalizations
Charlson score X1 based on outpatient encounters
The comparison group never used ICS during study period.Discussion
This analysis of COPD patients from two different
managed care organizations from different parts of
the United States found that patients who used ICS,
LABA, or ICS plus LABA had better survival than
patients who were only using short-acting bronch-
odilators, and that this survival benefit was
preserved even after adjustment for the other
clinical factors likely to affect survival, including
age, disease severity, comorbid diseases, and
smoking history. We found that COPD patients who
had a concurrent diagnosis of asthma had better
survival than those who did not, but the benefits of
ICS therapy with or without LABA were preserved
after adjusting for asthma in the models, and the
benefits of combined ICS/LABA therapy were still
significant even after excluding all persons who had
ever had a ICD-9 code for asthma from the cohort.
The ICS, LABA, and ICS+LABA treatment benefits
were still maintained after application of different
cohort inclusion criteria for minimum treatment
duration or intensity, and the hazard ratios for the
combined treatment group actually decreased as
the minimum exposure criteria increased. The
benefits of treatment with LABA alone were less
consistently significant across models, perhaps
because this was a relatively small group and
the hazard function was less stable. Inclusion of
ICS treatment during the follow-up period as ar ICS use during the follow-up period, ICS group and
Hazard ratio 95% confidence limits w2 Pr4w2
0.73 0.42 1.27 1.23 0.27
1.04 0.71 1.54 0.05 0.83
p 1.41 0.85 2.32 1.75 0.19
1.46 1.02 2.09 4.30 0.04
2.12 0.92 4.87 3.11 0.08
2.56 1.14 5.73 5.18 0.02
4.44 2.03 9.71 13.96 o0.001
1.16 0.88 1.53 1.13 0.29
2.06 1.36 3.12 11.61 o0.001
3.51 2.20 5.61 27.72 o0.001
1.19 0.73 1.93 0.47 0.49
1.30 0.81 2.09 1.19 0.27
1.26 0.85 1.88 1.32 0.25
0.77 0.53 1.12 1.86 0.17
0.82 0.29 2.29 0.14 0.70
0.69 0.32 1.49 0.91 0.34
1.35 0.90 2.04 2.09 0.15
1.10 0.81 1.48 0.36 0.55
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COPD survival and inhaled corticosteroids 605time-dependent variable in the model causes an
apparent loss of the survival advantage in the
treated group and ICS do not appear to have any
benefit during the follow-up period. However,
including ICS as a time-dependent variable does
not improve the goodness of fit of the model.
Furthermore, we found that use of ICS and other
respiratory drugs during the follow-up period is
clearly affected by changes in clinical status, and
therefore the independence assumption between
treatment and outcome that is essential for valid
time-dependent modeling is violated.
The major limitations of this study are the same
as those of most non-randomized study designs. In
particular, there may be patient factors associated
with treatment groups that caused them to have
better survival but were not directly the result of
the medication. The fact that there are differences
in the demographic characteristics between the
treated and comparison groups, and that substan-
tially more of the patients in the treatment groups
were also labeled with asthma, suggests that this
could be the case in this study. Misclassification
between COPD and asthma is always a difficult issue
in a database study, but because survival continued
to be better in the treated groups even after
removal of anyone ever labeled with an ICD-9 code
for asthma, it does not appear that misclassifica-
tion errors explain the entire treatment benefit. It
may be that patients who have both been labeled
with diagnoses of COPD and asthma simply have a
better prognosis than those who just have COPD,
but most large longitudinal studies have found that
persons with COPD who also have airway hyper-
responsiveness are actually more likely to have an
accelerated decline in lung function,39,43,44 and
poorer survival.38
Retrospective or cross-sectional studies are also
likely to be affected by confounding by indication,
meaning that patients with more severe disease or
who are otherwise unstable may be more or less
aggressively treated than other patients and sub-
sequent elevated risk estimates associated with
drug use may be due more to disease severity than
to a direct adverse drug effect.45 However, in this
study where a protective effect of the more
aggressive treatment was observed, patients in
the treated groups tended to have more severe
COPD than those in the comparison group. There-
fore, any confounding by indication in this study
would likely lead to an underestimate of the
benefit observed. It is very difficult to account
and adjust for differences in compliance with
treatment in a non-interventional study, particu-
larly during the follow-up period, but again this is
likely to result in a bias towards the null sincepatients who rarely use the ICS and/or LABA
treatments should more closely resemble the
comparison group and dilute any benefit among
those who used the medicine more frequently
during the follow-up period. Nevertheless, results
of observational studies provide important hypoth-
esis generating or complimentary real-world evi-
dence to those from randomized clinical trials, as
well as information about clinical effectiveness
that may be difficult to extrapolate from clinical
trials data.46,47
In our study, COPD patients from the Kaiser–
Georgia cohort appeared to have better survival
than those from the LHP. We are not able to know
whether this is due to a true difference in survival
or to differences in disease diagnosis or manage-
ment. Patients at Kaiser–Georgia tended to be
younger so they may have been diagnosed earlier or
treated more intensively, or the models may have
simply not adequately adjusted for the age
differences between the two populations (residual
confounding). Conversely, coding practices may
have differed between HMOs, leading to differ-
ences in our capture of COPD patients. Since our
model adjusted for COPD severity using proxy
measures of disease severity based on the number
of visits and admissions with a COPD diagnosis code,
differences between HMOs in either coding prac-
tices or referrals could result in over- or under-
adjustment for disease severity.
We found a survival benefit from ICS use was very
similar to that found in a study of similar design by
Soriano et al., who observed a hazard ratio of 0.68
for treatment to fluticasone propionate, compared
to our HR of 0.59 for any ICS treatment.33 In this
study, 80% of treated versus 63% of the reference
group had a history of asthma, suggesting the
problem of overlap between asthma and COPD
may be an even greater problem in the United
Kingdom GPRD. Our results are also similar to those
found by Sin and Tu in a study using the provincial
database for Ontario, despite the fact that this
Canadian population was restricted to persons aged
65 and older who had been admitted to a hospital
with COPD, the population had a higher Charlson
index score, and the researchers were not able to
control for asthma as a confounding factor.32 Using
the Ontario database, Sin has also found an
apparent dose–response relationship between ICS
use and survival in COPD.48 The consistency and
strength of the association between improved
survival and ICS use in COPD cohorts from three
different countries that have very different health-
care systems and population demographics in-
creases the probability that this is a causal
association.
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studies by Suissa and by Fan et al., both of whom
relied on a time-dependent analysis and showed
that ICS use was not associated with a treatment
benefit.34–36 There is no indication in any of these
manuscripts that the independence assumption
between changes in clinical status and treatment,
which is vital to time-dependent modeling, was
tested. Because the standard approach to COPD
treatment is to escalate treatment in response to
clinical signs and symptoms, independence be-
tween clinical status and treatment seems unli-
kely.1,2
The issue of immortal time bias, wherein persons
in the treated groups have an advantage because
they have to survive longer before their follow-up
period started, is cited by these studies as a
significant bias. However, this bias is in fact very
small: Sin demonstrated that immortal time bias
does not explain the entire survival benefit seen in
the Ontario cohort.49 Because our study design
required that both the treated and comparison
groups have 90 days exposure to a respiratory drug,
it is less susceptible to immortal time bias. Persons
in the combined ICS–LABA group did have a much
longer accrual period than the other groups,
leading to the potential for an immortal time bias
for that group only. However, even after realloca-
tion of their immortal time to the comparison
group, the combined ICS–LABA group continues to
have a rate ratio of 0.51 in favor of reduced
mortality. More recently, Kiri et al. have published
another observational study using the GPRD data-
base in which they examined the survival benefit of
ICS in COPD using two approaches that are free of
immortal time bias: the propensity score method,
and a matched nested case-control analysis.50 Both
methods found a significant risk reduction asso-
ciated with ICS use (hazard ratios 0.69 (95% CI,
0.52–0.93), and 0.71 (95% CI, 0.56–0.90), respec-
tively). Immortal time bias simply does not account
for the survival benefit associated with ICS treat-
ment in observational studies.
No published clinical study of ICS treatment of
COPD has examined survival as it primary outcome,
and until a current prospective randomized clinical
trial is complete, the question as to whether ICS
treatment affects survival remains open.51 None-
theless, a causal relationship between ICS use and
improved survival appears very plausible based on
what is known about COPD disease mechanisms and
observations from clinical studies. The most likely
means by which ICS could impact survival is through
reduction in the number and severity of COPD
exacerbations and to a lesser known degree
through anti-inflammatory effects in and outsidethe lung. Exacerbations can be life-threatening in
persons with advanced disease; they were asso-
ciated with an 11% in-hospital death rate and 20%
60-day death rate in a multi-center study of 1016
persons admitted for COPD exacerbation.52 Exacer-
bation events may also contribute to the progres-
sive loss in baseline respiratory function
characteristic of COPD patients.53,54 COPD patients
who have more frequent exacerbations have worse
quality of life,55–57 and low quality of life is a
predictor of death in COPD.58
There is little information about how the pattern
of airway inflammation associated with COPD,
characterized by increased numbers of CD8+ T
lymphocytes, mononuclear cells, neutrophils, and
macrophages, is related to exacerbation events,
and ICS have been criticized because they generally
do not affect these inflammatory cells.6,14,15 How-
ever, in a randomized placebo-controlled biopsy
study that examined COPD patients who did not
have airway hyper-responsiveness or evidence of
asthma, inhaled fluticasone significantly reduced
the number of subepithelial mast cells and the
CD8:CD4 ratio in the epithelium, and the CD4+ cells
were significantly increased in the placebo group in
both the subepithelium and epithelium.9 Mast cells
are important in the pathogenesis of asthma,59
increased mast cells are found in the subepithelium
of chronic bronchitis,60 and it is possible that
suppression of mast cells reduces susceptibility to
exacerbations in COPD even when asthma features
are not present.9 In acute exacerbations of COPD,
brief courses of systemic corticosteroids have been
shown to reduce the risk for treatment failure
(respiratory failure, death, or need for intensified
therapy) for up to 90 days,61 even though many
exacerbations are attributable to viral or bacterial
infections62,63 and are associated with a neutro-
philic inflammatory response.64 In summary,
although knowledge about the mechanisms of
COPD pathogenesis and acute exacerbations is far
from complete, empirical and biopsy evidence
suggests that ICS beneficially suppress components
of the inflammatory response that increase sus-
ceptibility to exacerbations, and may also reduce
the risk for complications when exacerbations do
occur.
This and other recent COPD studies that have
observed positive clinical effects of treatment with
ICS and LABA suggest that it is time to re-consider
primary outcomes measures for clinical studies of
this disease. Guidelines continue to emphasize that
ICS have not modified the long-term decline in FEV1
in clinical trials and thus note uncertainty about
the long-term benefits of ICS in COPD (GOLD, ATS/
ERS). The outcomes of most importance to patients
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frequency and severity of exacerbations, improve-
ment in quality-of-life, and prolonged survival. A
rapidly growing body of evidence suggests that ICS,
and certainly the combination of ICS with LABA,
have substantial impact on these clinically impor-
tant measures. The primary outcome measures in
clinical cardiovascular disease research have been
for many years either serious clinical events or
mortality, and as a result mortality rates for
cardiovascular disease have fallen by more than
half over the last three decades. The growing body
of research in COPD suggests that we can in fact
have a substantial impact on survival in this
disease, and more clinical trials in COPD need to
be designed with survival as their primary outcome
measure.Acknowledgements
The investigators are grateful to Hans Petersen and
Ellen Leibman for data programming, Ann Von
Worley, Melanie Powell-Eley, and Jeanne Jordan
for abstraction of medical records, and Mary
Davidson for data entry.References
1. The GOLD Scientific Committee. Global strategy for the
diagnosis, management, and prevention of COPD, 2004
Update. Accessed at www.GOLDCOPD.com, December 1,
2004.
2. Celli BR, MacNee W, Agusti A, et al. Standards for the
diagnosis and treatment of patients with COPD: a summary
of the ATS/ERS position paper. Eur Respir 2004;23:932–46.
3. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM.
Cellular and structural bases of chronic obstructive pulmon-
ary disease. Am J Respir Crit Care Med 2001;163:1304–9.
4. O’Byrne PM, Postma DS. The many faces of airway
inflammation. Asthma and chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 1999;159:S41–63.
5. Calverley PMA. Inhaled corticosteroids are beneficial in
chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2000;161:341–2.
6. Barnes PJ. Inhaled corticosteroids are not beneficial in
chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2000;161:342–4.
7. Postma DS, Kersjens HAM. Are inhaled glucocorticosteroids
effective in chronic obstructive pulmonary disease? Am J
Respir Crit Care Med 1999;160:S66–71.
8. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on
systemic markers of inflammation in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2004;170:
760–5.
9. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC.
The effects of inhaled fluticasone on airway inflammation in
chronic obstructive pulmonary disease. A double-blind,placebo-controlled biopsy study. Am J Respir Crit Care
Med 2002;165:1592–6.
10. Balbi B, Majori M, Bertacco S, et al. Inhaled corticosteroids
in stable COPD patients—do they have effects on cells and
molecular mediators of airway inflammation? Chest 2000;
117:1633–7.
11. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled
corticosteroids reduce neutrophilic bronchial inflammation
in patients with chronic obstructive pulmonary disease.
Thorax 1998;53:583–5.
12. Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of
fluticasone propionate on sputum of patients with chronic
bronchitis and emphysema. Am J Respir Crit Care Med 1996;
153:616–21.
13. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized
beclomethasone in chronic bronchitis: improved pulmonary
function and diminished airway inflammation. Am Rev Respir
Dis 1992;146:389–95.
14. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews
JL, Barnes PJ. Effect of high dose inhaled steroid on cells,
cytokines, and proteases in induced sputum in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
1999;160:1635–9.
15. Keatings VA, Jatakanon A, Worsdell YM, Barnes PJ. Effects of
inhaled and oral glucocorticoids on inflammatory indices in
asthma and COPD. Am J Respir Crit Care Med 1997;155:
542–8.
16. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K,
Efthimiou J. Multicentre randomized placebo-controlled
trial of inhaled fluticasone propionate in patients with
chronic obstructive pulmonary disease. International COPD
Study Group. Lancet 1998;351:773–80.
17. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An
observational study of inhaled corticosteroid withdrawal in
stable chronic obstructive pulmonary disease. Respir Med
1999;93:161–8.
18. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA,
Maslen TK. Randomised, double blind, placebo controlled
study of fluticasone propionate in patients with moderate to
severe chronic obstructive pulmonary disease: the ISOLDE
trial. BMJ 2000;320:1297–303.
19. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled
corticosteroids in chronic obstructive pulmonary disease: a
systematic review of randomized placebo-controlled trials.
Am J Med 2002;113:59–65.
20. Spencer S, Calverley PM, Sherwood Berge P, et al. Health
status deterioration in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2001;163:
122–8.
21. Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G,
Van Herwaarden C. Effect of discontinuation of inhaled
corticosteroids in patients with chronic obstructive pulmon-
ary disease. Am J Respir Crit Care Med 2002;166:1358–63.
22. The Lung Health Study Research Group. Effect of inhaled
triamcinolone on the decline in pulmonary function in
chronic obstructive pulmonary disease. N Engl J Med 2000;
343:1902–9.
23. Mahler DA, Wire P, Horstman D, et al. Effectiveness of
fluticasone propionate and salmeterol combination deliv-
ered via the discus device in the treatment of chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2002;166:1084–91.
24. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol
and fluticasone in the treatment of chronic obstructive
pulmonary disease: a randomized controlled trial. Lancet
2003;361:449–56.
ARTICLE IN PRESS
D.W. Mapel et al.60825. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and
safety of budesonide/formoterol in the management of
chronic obstructive pulmonary disease. Eur Respir J 2003;
21:74–81.
26. Hanania NA, Darken P, Horstman D, et al. The efficacy and
safety of fluticasone propionate (250 mg)/salmeterol (50mg)
combined in the discus inhaler for the treatment of COPD.
Chest 2003;124:834–43.
27. Cazzola M, Dahl R. Inhaled combination therapy with long-
acting b2-agonists and corticosteroids in stable COPD. Chest
2004;126:220–37.
28. Van Grunsven PM, van Schayck CP, Derenne JP, et al. Long
term effects of inhaled corticosteroids in chronic obstructive
pulmonary disease: a meta-analysis. Thorax 1999;54:7–14.
29. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K.
Long-term effect of inhaled budesonide in mild and
moderate chronic obstructive pulmonary disease: a rando-
mised controlled trial. Lancet 1999;353:1819–23.
30. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term
treatment with inhaled budesonide in persons with mild
chronic obstructive pulmonary disease who continue smok-
ing. European Respiratory Society Study on Chronic Ob-
structive Pulmonary Disease. N Engl J Med 1999;340:
1948–53.
31. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ.
Inhaled corticosteroids reduce the progression of airflow
limitation in chronic obstructive pulmonary disease: a meta-
analysis. Thorax 2003;58:937–41.
32. Sin DD, Tu JV. Inhaled corticosteroids and the risk of
mortality and readmission in elderly patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2001;164:580–4.
33. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC.
Survival in COPD patients after regular use of salmeterol
and/or fluticasone propionate in general practice. Eur
Respir J 2002;20:1–7.
34. Suissa S. Effectiveness of inhaled corticosteroids in COPD:
immortal time bias in observational studies. Am J Respir Crit
Care Med 2003;168:49–53.
35. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in
chronic obstructive pulmonary disease and risk of death and
hospitalization. Am J Respir Crit Care Med 2003;168:1488–94.
36. Suissa S. Inhaled steroids and mortality in COPD: bias from
unaccounted immortal time. Eur Respir J 2004;23:391–5.
37. Fisher LD, Lin DY. Time-dependent covariates in the Cox
proportional-hazards regression model. Annu Rev Public
Health 1999;20:145–57.
38. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP.
Histamine airway hyper-responsiveness and mortality form
chronic obstructive pulmonary disease: a cohort study.
Lancet 2000;356:1313–7.
39. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD
mortality. Thorax 2001;56(Suppl 2):ii11–4.
40. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comor-
bidity index for use with ICD-9-CM administrative databases.
J Clin Epidemiol 1992;45:613–9.
41. Collett D. Modelling survival data in medical research, 2nd
ed. Boca Raton, FL: Chapman & Hall/CRC Press; 2003.
42. Allison PD. Survival analysis using the SASs system: a
practical guide. Cary, NC: SAS Institute Inc.; 1995.
43. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise
RA. Methacholine reactivity predicts changes with early
chronic obstructive pulmonary disease. The Lung Health
Study Research Group. Am J Respir Crit Care Med 1996;
153:1802–11.44. Rijcken B, Weiss ST. Longitudinal analyses of airway
responsiveness and pulmonary function decline. Am J Respir
Crit Care Med 1996;154:S246–9.
45. Singer JW, Willett JB. Applied longitudinal data analysis:
modeling change and event occurrence. New York: Oxford
University Press; 2003.
46. Benson K, Hartz AJ. A comparison of observational studies
and randomized, controlled trials. N Engl J Med 2000;342:
1878–86.
47. Concato J, Shah N, Horwitz RI. Randomized, controlled
trials, observational studies, and the hierarchy of research
designs. N Engl J Med 2000;342:1887–92.
48. Sin DD, Man SF. Inhaled corticosteroids and survival in
chronic obstructive pulmonary disease: does the dose
matter? Eur Respir J 2003;21:260–6.
49. Sin DD, Man SF, Tu JV. Inhaled glucocorticoids in COPD:
immortal time bias. Am J Respir Crit Care Med 2003;168:
126–7.
50. Kiri VA, Pride NB, Sorian JB, Vestbo J. Inhaled corticosteroids
in COPD: results from two observational designs free of
immortal time bias. Am J Respir Crit Care Med 2005;172:
460–4.
51. Samet JM. Inhaled Corticosteroids and chronic obstructive
pulmonary disease: new and improved evidence? Am J
Respir Crit Care Med 2005;172:407–8.
52. Connors Jr AF, Dawson NV, Thomas C, et al. Outcomes
following acute exacerbation of severe chronic obstructive
lung disease: the SUPPORT investigators (Study to under-
stand prognoses and preferences for outcomes and risks of
treatments) [published erratum appears in Am J Respir Crit
Care Med 1997;155:386]. Am J Respir Crit Care Med 1996;
154:959–67.
53. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000;161:1608–13.
54. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory
illnesses promote FEV1 decline in current smokers but not
ex-smokers with mild chronic obstructive lung disease:
results from the lung health study. Am J Respir Crit Care
Med 2001;164:358–64.
55. Osman IM, Godden DJ, Friend JA, et al. Quality of life and
hospital re-admission in patients with chronic obstructive
pulmonary disease. Thorax 1997;52:67–71.
56. Traver GA. Measures of symptoms and life quality to predict
emergent use of institutional health care resources in
chronic obstructive airways disease. Heart Lung 1988;17:
689–97.
57. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of
exacerbation on quality of life in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
1998;157:1418–22.
58. Fan VS, Curtis JR, Shin-Ping T, McDonell MB, Fihn SD. Using
quality of life to predict hospitalization and mortality in
patients with obstructive lung diseases. Chest 2002;122:
429–36.
59. Amin K, Ludviksdottir D, Janson C, Nettelbladt O, et al.
Inflammation and structural changes in the airways of
patients with atopic and nonatopic asthma. Am J Respir
Crit Care Med 2000;162:2295–301.
60. Pesci A, Rossi GA, Bertorelli G, Aufiero A, Zanon P, Olivieri D.
Mast cells in the airway lumen and bronchial mucosa of
patients with chronic bronchitis. Am J Respir Crit Care Med
1994;149:1311–6.
61. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect
of systemic glucocorticoids on exacerbations of chronic
ARTICLE IN PRESS
COPD survival and inhaled corticosteroids 609obstructive pulmonary disease. N Engl J Med 1999;340:
1941–7.
62. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respi-
ratory viruses, symptoms, and inflammatory markers
in acute exacerbations and stable chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2001;164:
1618–23.63. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of
bacteria and exacerbations of chronic obstructive pulmon-
ary disease. N Engl J Med 2002;347:465–71.
64. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJB,
Murphy TF. Airway inflammation and etiology of acute
exacerbations of chronic bronchitis. Chest 2000;118:
1557–65.
